• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alumis Inc. - Common Stock (NQ: ALMS )

    11.32 +0.09 (+0.80%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 71,372
    Open 11.11
    Bid (Size) 11.32 (19)
    Ask (Size) 11.36 (5)
    Prev. Close 11.23
    Today's Range 11.11 - 11.80
    52wk Range 9.540 - 13.53
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
    HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers... 
    Via Benzinga

    Performance

    YTD
    -14.89%
    -14.89%
    1 Month
    +6.09%
    +6.09%
    3 Month
    -10.80%
    -10.80%
    6 Month
    -14.89%
    -14.89%
    1 Year
    -14.89%
    -14.89%

    More News

    Read More
    This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
    Via Benzinga
    Jim Cramer Says He's Buying 'Some Target,' But Dismisses SoundHound AI As 'Meme Stock'
    Via Benzinga
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Alumis to Participate in Upcoming September Investor Conferences
    From Alumis Inc.
    Via GlobeNewswire
    ALMS Stock Earnings: Alumis Reported Results for Q2 2024
    Via InvestorPlace
    Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
    From Alumis Inc.
    Via GlobeNewswire
    Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
    From Alumis Inc.
    Via GlobeNewswire
    Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
    Via Benzinga
    Ardent Health Slips After Downsized IPO
    Via Talk Markets
    Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering
    Via Benzinga
    Topics Initial Public Offering
    Exposures Securities Market
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.